Pharma Packaging

Bormioli Pharma, an international leader in the production of containers for the pharmaceutical industry, and Pierre Fabre, a French pharmaceutical and dermo-cosmetic group present in more than 100 countries, are consolidating their partnership started in 2020 through an innovative initiative in eco-design and sustainable development.

"Our increased decoration capability allows us to bring in-house a service that was previously outsourced. In doing so, we will be able to speed up delivery times and cut carbon footprint of our ‘Made in Europe’ solutions."

€1 million has been invested in the creation of the decoration centre. The site is supported by a four-tonne metal structure to create an open space with room to expand. A climate control system and air filters create the ideal conditions for decoration. The centre is staffed by 36 employees, with specialist training in decorating techniques.

"Our increased decoration capability allows us to bring in-house a service that was previously outsourced. In doing so, we will be able to speed up delivery times and cut carbon footprint of our ‘Made in Europe’ solutions."

€1 million has been invested in the creation of the decoration centre. The site is supported by a four-tonne metal structure to create an open space with room to expand. A climate control system and air filters create the ideal conditions for decoration. The centre is staffed by 36 employees, with specialist training in decorating techniques.

• Proof of Concept (PoC) successfully provides primary packaging with a unique ID to access its own trustworthy digital twin
• Users gain immediate access to quality and process data of products at the item level
• Digital authenticity and trust are ensured through patented crypto anchors and digital certificates

Merck, a leading science and technology company, and Gerresheimer AG, Duesseldorf, Germany, a leading provider of healthcare solutions and drug delivery systems for pharma, biotech and cosmetics, jointly developed a digital twin solution to further e

Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones following the close of the transaction.

As well as coronavirus, Mesa Biotech's point-of-care platform can also detect Influenza A and B, respiratory syncytial virus (RSV) and Strep A. The company is based in San Diego, California and has approximately 500 employees and revenues in 2020 of approximately $45 million.